(AGENPARL) – lun 24 febbraio 2025 Lund, Sweden, 24 February 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm:
HNSA) today announced it will attend TD Cowen’s 45th Annual Health Care
Conference taking place on March 3 – 5, 2025, at the Boston Marriott Copley
Place in Boston, MA. The conference incorporates presentations, fireside chats
and innovative panel discussions, moderated by members of the TD Cowen research
team, that focus on various aspects of the Health Care industry.
Søren Tulstrup, President and CEO, Hansa Biopharma, will hold a presentation on
Wednesday 5 March at 1:50PM ET. The presentation will be subsequently available
on Hansa’s corporate
website (https://www.hansabiopharma.com/investors/presentations-events/).
Hansa management will be available for meetings at the conference. If you are
interested in meeting with the management team, please contact Hansa Biopharma
To learn more about Hansa Biopharma see the latest Corporate
Presentation here. (https://www.hansabiopharma.com/investors/presentations
-events/) The latest investor presentation can be
viewed here (https://www.hansabiopharma.com/investors/financial-reports/).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3hodwu3XoHui7ADjmTafRxmFH2kZLmqYmeaAcBmdUaoG1deGjvsptPmq4CKRxC7HxsbwmakzSCYoj3K5RXSBuZUKn1qYqMpdNB9FGybRSXDsgc.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3hodwu3XoHui7ADjmTafRxmFH2kZLmqYmeaAcBmdUaoG1deGjvsptPmq4CKRxC7HxsbwmakzSCYoj3K5RXSBuZUKn1qYqMpdNB9FGybRSXDsgc.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content